Terms: = Liver cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
51 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
3. Safety of Sonazoid in Assisting High-Intensity Focused Ultrasound Ablation Therapy for Advanced liver Malignant Lesions: A Single-Arm Clinical Study.
Zhou H; Li F; Luo L; Xiong X; Zhou K; Zhu H; Zhang J; Li P
Ultrasound Med Biol; 2024 Jan; 50(1):134-141. PubMed ID: 37865612
[TBL] [Abstract] [Full Text] [Related]
4. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract] [Full Text] [Related]
5. Selpercatinib monotherapy in a Chinese patient with ret fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBretTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.
Ni B; He X; Zhang Y; Wang Z; Dong Z; Xia X; Zhao G; Cao H; Zhu C; Li Q; Liu J; Chen H; Zhang Z
Cell Oncol (Dordr); 2023 Apr; 46(2):315-330. PubMed ID: 36808605
[TBL] [Abstract] [Full Text] [Related]
7. retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts.
Zhu W; Qiu Z; Yan H; Zhong Z; Jiang W; Zhang F; Gao F
Diagn Interv Radiol; 2022 Nov; 28(6):616-620. PubMed ID: 36550763
[TBL] [Abstract] [Full Text] [Related]
8. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
9. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract] [Full Text] [Related]
10. Application of histology-agnostic treatments in metastatic colorectal cancer.
Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
[TBL] [Abstract] [Full Text] [Related]
11. Novel Therapeutics and treatment Strategies for Medullary Thyroid cancer.
Walgama E; Busaidy N; Zafereo M
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):379-389. PubMed ID: 35662447
[TBL] [Abstract] [Full Text] [Related]
12. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract] [Full Text] [Related]
13. Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment.
Wohlfeil SA; Häfele V; Dietsch B; Weller C; Sticht C; Jauch AS; Winkler M; Schmid CD; Irkens AL; Olsavszky A; Schledzewski K; Reiners-Koch PS; Goerdt S; Géraud C
J Transl Med; 2022 Feb; 20(1):62. PubMed ID: 35109875
[TBL] [Abstract] [Full Text] [Related]
14. Genomic characterization of hepatoid tumors: context matters.
Lawlor RT; Mafficini A; Sciammarella C; Cantù C; Rusev BC; Piredda ML; Antonello D; Grimaldi S; Bonizzato G; Sperandio N; Marchegiani G; Malleo G; Pea A; Salvia R; Mombello A; Mazzoleni G; Nottegar A; Hanspeter E; Riva G; Tomezzoli A; Bencivenga M; de Manzoni G; Pedron S; Paolino G; Mattiolo P; Brosens LA; Silvestris N; Fassan M; Cooke SL; Beer PA; Milella M; Adsay VN; Cheng L; Scarpa A; Luchini C
Hum Pathol; 2021 Dec; 118():30-41. PubMed ID: 34562502
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract] [Full Text] [Related]
16. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.
Wang D; Day EA; Townsend LK; Djordjevic D; Jørgensen SB; Steinberg GR
Nat Rev Endocrinol; 2021 Oct; 17(10):592-607. PubMed ID: 34381196
[TBL] [Abstract] [Full Text] [Related]
17. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.
Hou Y; Liang HL; Yu X; Liu Z; Cao X; Rao E; Huang X; Wang L; Li L; Bugno J; Fu Y; Chmura SJ; Wu W; Luo SZ; Zheng W; Arina A; Jutzy J; McCall AR; Vokes EE; Pitroda SP; Fu YX; Weichselbaum RR
Sci Transl Med; 2021 Feb; 13(582):. PubMed ID: 33627484
[TBL] [Abstract] [Full Text] [Related]
18. Effect of Lenvatinib on a Patient with Medullary Thyroid Carcinoma liver Metastasis Caused by Multiple Endocrine Neoplasia Type 2A.
Sato H; Saito Y; Inomoto C; Suzuki Y
Tokai J Exp Clin Med; 2020 Apr; 45(1):18-23. PubMed ID: 32219805
[TBL] [Abstract] [Full Text] [Related]
19. A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Yamano T; Kubo S; Tomita N
Cancer Med; 2020 May; 9(10):3337-3343. PubMed ID: 32168428
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with ret Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Yang X; Shi J; Chen X; Jiang Y; Zhao H
Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
[TBL] [Abstract] [Full Text] [Related]
[Next]
